Skip to main content
. 2022 Sep 26;28(20):4494–4508. doi: 10.1158/1078-0432.CCR-22-0543

Figure 5.

Figure 5. Changes in immune gene expression after chemotherapy in ER+HER2– and TNBC RCB II/III disease. A, Heatmap showing expression of immune profiling gene set in matched pretreatment and residual disease ER+HER2– samples. B, Heatmap showing expression of the immune profiling gene set in matched pretreatment and residual disease TNBC samples. C, Venn diagram showing upregulated or downregulated genes after chemotherapy treatment in ER+HER2– and TNBC samples. D, STRING analysis of known interactions between hit genes downregulated in ER+HER2– residual disease samples, compared with pretreatment. E, STRING analysis of known interactions between hit genes downregulated in TNBC residual disease samples, compared with pretreatment. F, STRING analysis of known interactions between hit genes upregulated in TNBC residual disease samples, compared with pretreatment. G, Expression of NK-related marker genes in PD-L1/PD-1–low melanoma tumors stratified by response to anti–PD-1 therapy.

Changes in immune gene expression after chemotherapy in ER+HER2– and TNBC RCB II/III disease. A, Heatmap showing expression of immune profiling gene set in matched pretreatment and residual disease ER+HER2– samples. B, Heatmap showing expression of the immune profiling gene set in matched pretreatment and residual disease TNBC samples. C, Venn diagram showing upregulated or downregulated genes after chemotherapy treatment in ER+HER2– and TNBC samples. D, STRING analysis of known interactions between hit genes downregulated in ER+HER2– residual disease samples, compared with pretreatment. E, STRING analysis of known interactions between hit genes downregulated in TNBC residual disease samples, compared with pretreatment. F, STRING analysis of known interactions between hit genes upregulated in TNBC residual disease samples, compared with pretreatment. G, Expression of NK-related marker genes in PD-L1/PD-1–low melanoma tumors stratified by response to anti–PD-1 therapy.